Description: Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Home Page: www.galmedpharma.com
16 Abba Hillel Road
Ramat Gan,
5250608
Israel
Phone:
972 3 693 8448
Officers
| Name | Title |
|---|---|
| Mr. Allen Baharaff | Co-Founder, President, CEO & Chairman |
| Mr. Doron Cohen | Chief Financial Officer |
| Mr. Guy Nehemya | COO & Data Protection Officer |
| Mr. Yohai Stenzler CPA | Chief Accounting Officer |
| Dr. Liat Hayardeny MBA, Ph.D. | Chief Scientific Officer |
| Dr. Tali Gorfine | Medical Consultant |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.0034 |
| Price-to-Book MRQ: | 0.2568 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 3 |